With just days left before the implementation of the US-Korea free trade agreement Washington is drawing attention to a little publicized area of the trade treaty, the part covering the pricing of medicine in Korea. The US says it wants more transparency; the Korean pharmaceutical industry says it wants to maintain control over pricing domestically.
Negotiations of the Transpacific Partnership Agreement (TPP) have turned to discussions of the pharmaceutical reimbursement chapter. This issue is highly controversial and represents a very recent shift in US trade policy.
After four years of negotiations, campaigners fear India is about to sign a trade deal with the EU which will stop the flow of cheap life-saving drugs to the developing world
Supporting the ongoing Global Week of Action on the EU-India FTA, Pauline Londeix of Act Up-Paris today confronted the European Commission for Trade, Karel de Gucht at a “Civil Society dialogue on Trade, Growth and development” at the European Commission. De Gucht reportedly leaves for India tomorrow for the EU-India Summit on 10th February 2012 where the E.C. is putting pressure on the Indian government to announce political trade-offs in the EU-India FTA.
Fiji Network for Positive People believes that the Asia Pacific Network of People Living with HIV/AIDS meeting will be an opportune time to advocate for continuing availability of generic Anti Retro Viral treatment in the face of threats from Free Trade Agreement negotiations.
Under the Korea-US Free Trade Agreement (KORUS FTA), Korean civil servants would be excluded from the Health Insurance Review and Assessment Service (HIRA)’s process of price determination. Instead independent review procedures could be used to set prices for medicines and medical supplies. This has caused concern among health care groups who worry that multinational pharmaceutical companies could use the independent review procedure to change the Korean government’s medicine prices.
As the 14th round of negotiations on the EU-India free trade agreement is held in Delhi, an NGO working in the health sector has urged the European Union not to push India to accept IP provisions in the deal
DNP+ believes that IP should be completely be removed from the trade
The scholars’ analysis concludes that the "US proposals, if adopted,
would upset the current international framework balancing the minimum
standards for exclusive rights for media and technology owners, on the
one hand, and the access rights of the public, competitors, innovators
and creators, on the other."
Citizen Trade Campaign has released this proposed text from the US on technical barriers to trade relating to medical devices and pharmaceuticals under the Trans Pacific Partnership
The Indian pharmaceuticals and chemicals industry will be among the biggest beneficiaries of a free trade agreement between the GCC and India, a leading banker in the region has said.
The Obama administration on Monday sought to allay concerns that the U.S. push for stronger drug patent protections in a Transpacific trade deal would raise the cost of life-saving treatments out of the reach of the region’s poor people.
Call for all civil society groups, people living with HIV, all communities facing communcable, chronic and/or non-communicable diseases in the TPPA signatory countries to join forces to halt any & all trade agreements that restrict access to generic medicines.
Australia leads the world in many areas of public health but the Federal Government could be negotiating our achievements away, according to Dr Patricia Ranald, Convenor, Australian Fair Trade and Investment Network
The 10th International Conference on AIDS in Asia and the Pacific (ICAAP10) has been turned upside down completely
An anti-Free Trade Agreement protest that took place outside an International Congress on AIDS in the Asia Pacific (ICAAP) in Busan, South Korea, on 27 August was violently attacked by police.
Last week, a group of seven House Democrats, led by Rep. Henry Waxman (D-CA), sought to have the 12-year data exclusivity period provided by the biosimilar approval pathway of the US’ Patient Protection and Affordable Care Act excluded from the Trans-Pacific Partnership agreement
India’s Department of Pharmaceuticals will take up issues with the Commerce Ministry regarding the proposed Trans Pacific Partnership Agreement which is likely to have adverse impact on the Indian pharma products, and other such Free Trade Agreements in the pipeline.
The new strategy is to treat people in Egypt, Paraguay, Turkmenistan or China — middle-income countries, all — as if they or their governments could pay hundreds or even thousands of dollars a year each for AIDS drugs.
CETA IPR chapter will likely have a slight positive effect on specific industries in the EU, such as agri-food companies using geographical indications. It would also benefit the Canadian publishing industry and the innovative pharmaceutical industry. At the same time, an IPR chapter in CETA could lead to notable negative effects in Canada, for example via higher prices on educational and pharmaceutical products.